Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-10-2000 | Meeting abstract

Sclerosing lymphocytic lobulitis (SLL): a diagnostic challenge

Authors: S Dutta, L Campbell, RM Watkins, C Teasdale, DM Lee, PA Jones

Published in: Breast Cancer Research | Special Issue 2/2000

Login to get access

Excerpt

SLL is a relatively rare condition first described in 1984. The clinical presentation, ultrasonographic and mammographic appearances and histology in 10 patients have been reviewed. The median age was 47 years (range 23-70 years). Eight patients presented with a hard mass (mean size 2.0 cm) and two patients had ill-defined thickening. Ultrasonography showed an irregular hypoechoeic area in four cases. There was non-visualisation of the lump in three cases, a discrete mass in two cases and an area of distortion in another. Mammography was performed in six patients which showed an appearance suggestive of carcinoma in two, increased density with distortion in one, dense glandular tissue in two and an increased density with a lucent mass in another. Fine needle aspiration cytology was performed in nine cases and reported as C1 in two, C2 in three, C3 in two and C4 in two patients. Core biopsy in eight cases showed SLL in four and B2 in four cases. Surgical biopsy confirmed the diagnosis of SLL in nine patients. …
Metadata
Title
Sclerosing lymphocytic lobulitis (SLL): a diagnostic challenge
Authors
S Dutta
L Campbell
RM Watkins
C Teasdale
DM Lee
PA Jones
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr219

Other articles of this Special Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine